Last 12 months
Inside the activity.
5 purchase rows · 0 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 0 |
| Dec 2025 | 1 | 0 |
| Jan 2026 | 1 | 0 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 2 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 1 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 30, 2020 Filed Oct 1, 2020 13:37 UTC |
TALOR EYALChief Scientific Officer
|
GrantCommon Stock | 188 | $12.75 | $2,397.00 |
DisclosureSEC source: 0001236031-20-000030 · primary_doc.xml · nonDerivative · entry 1 TALOR EYAL · CIK 0001238028 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 119,043 Read SEC document |
| September 30, 2020 Filed Oct 1, 2020 13:33 UTC |
PRICHEP PATRICIA BSenior Vice President
|
GrantCommon Stock | 297 | $12.75 | $3,786.75 |
DisclosureSEC source: 0001236031-20-000029 · primary_doc.xml · nonDerivative · entry 1 PRICHEP PATRICIA B · CIK 0001236215 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 206,134 Read SEC document |
| September 30, 2020 Filed Oct 1, 2020 13:30 UTC |
KERSTEN GEERT RDirector · Chief Executive Officer
|
GrantCommon Stock | 335 | $12.75 | $4,271.25 |
DisclosureSEC source: 0001236031-20-000028 · primary_doc.xml · nonDerivative · entry 1 KERSTEN GEERT R · CIK 0001236030 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,120,146 Read SEC document |
| June 30, 2020 Filed Jul 1, 2020 14:40 UTC |
ZIMMERMAN DANIEL HSenior VP, Research
|
GrantCommon Stock | 228 | $14.92 | $3,401.76 |
DisclosureSEC source: 0001236031-20-000027 · primary_doc.xml · nonDerivative · entry 1 ZIMMERMAN DANIEL H · CIK 0001236028 · Senior VP, Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 114,911 Read SEC document |
| June 30, 2020 Filed Jul 1, 2020 14:36 UTC |
TALOR EYALChief Scientific Officer
|
GrantCommon Stock | 160 | $14.92 | $2,387.20 |
DisclosureSEC source: 0001236031-20-000026 · primary_doc.xml · nonDerivative · entry 1 TALOR EYAL · CIK 0001238028 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 118,855 Read SEC document |
| June 30, 2020 Filed Jul 1, 2020 14:33 UTC |
PRICHEP PATRICIA BSenior VP, Operations
|
GrantCommon Stock | 245 | $14.92 | $3,655.40 |
DisclosureSEC source: 0001236031-20-000025 · primary_doc.xml · nonDerivative · entry 1 PRICHEP PATRICIA B · CIK 0001236215 · Senior VP, Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 205,837 Read SEC document |
| June 30, 2020 Filed Jul 1, 2020 14:28 UTC |
KERSTEN GEERT RDirector · CEO
|
GrantCommon Stock | 286 | $14.92 | $4,267.12 |
DisclosureSEC source: 0001236031-20-000024 · primary_doc.xml · nonDerivative · entry 1 KERSTEN GEERT R · CIK 0001236030 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,119,811 Read SEC document |
| April 20, 2020 Filed Apr 20, 2020 21:05 UTC |
Watson Robert EugeneDirector
|
GrantOptions · Derivative | 128,000 | $0.01 Strike: $10.93 | $1,280.00 |
DisclosureSEC source: 0001236031-20-000023 · primary_doc.xml · derivative · entry 1 Watson Robert Eugene · CIK 0001511858 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 378,000 Underlying: Common Stock · 128,000 shares Expires 2030-04-19 F1 · derivative.exercise_date: These stock options are performance based. Each option entitles the holder to purchase one share of the Company's common stock at a price of $10.93 per share. The stock options vest upon the achievement of the following performance goals: i) 25% of the options will vest when the closing price of the Company's common stock exceeds $20.00 for ten consecutive trading days; ii) 50% of the options will vest when the closing price of the Company's common stock exceeds $25.00 for ten consecutive trading days; iii) 75% of the options will vest when the closing price of the Company's common stock exceeds $30.00 for ten consecutive trading days; and iv) 100% of the options will vest when either (a) the filing of the first marketing application for any pharmaceutical based upon the Company's Multikine technology in any of the USA, Canada, UK, Germany, France, Italy, Spain, Japan, or Australia or (b) the closing price of the Company's common stock exceeds $40.00 for ten consecutive trading days. Read SEC document |
| April 20, 2020 Filed Apr 20, 2020 21:02 UTC |
BAILLAVOINE BRUNO JEAN-MARIEDirector
|
GrantOptions · Derivative | 128,000 | $0.01 Strike: $10.93 | $1,280.00 |
DisclosureSEC source: 0001236031-20-000022 · primary_doc.xml · derivative · entry 1 BAILLAVOINE BRUNO JEAN-MARIE · CIK 0001646989 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 405,500 Underlying: Common Stock · 128,000 shares Expires 2030-04-19 F1 · derivative.exercise_date: These stock options are performance based. Each option entitles the holder to purchase one share of the Company's common stock at a price of $10.93 per share. The stock options vest upon the achievement of the following performance goals: i) 25% of the options will vest when the closing price of the Company's common stock exceeds $20.00 for ten consecutive trading days; ii) 50% of the options will vest when the closing price of the Company's common stock exceeds $25.00 for ten consecutive trading days; iii) 75% of the options will vest when the closing price of the Company's common stock exceeds $30.00 for ten consecutive trading days; and iv) 100% of the options will vest when either (a) the filing of the first marketing application for any pharmaceutical based upon the Company's Multikine technology in any of the USA, Canada, UK, Germany, France, Italy, Spain, Japan, or Australia or (b) the closing price of the Company's common stock exceeds $40.00 for ten consecutive trading days. Read SEC document |
| April 20, 2020 Filed Apr 20, 2020 20:58 UTC |
YOUNG PETER RDirector
|
GrantOptions · Derivative | 128,000 | $0.01 Strike: $10.93 | $1,280.00 |
DisclosureSEC source: 0001236031-20-000021 · primary_doc.xml · derivative · entry 1 YOUNG PETER R · CIK 0001238029 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 416,300 Underlying: Common Stock · 128,000 shares Expires 2030-04-19 F1 · derivative.exercise_date: These stock options are performance based. Each option entitles the holder to purchase one share of the Company's common stock at a price of $10.93 per share. The stock options vest upon the achievement of the following performance goals: i) 25% of the options will vest when the closing price of the Company's common stock exceeds $20.00 for ten consecutive trading days; ii) 50% of the options will vest when the closing price of the Company's common stock exceeds $25.00 for ten consecutive trading days; iii) 75% of the options will vest when the closing price of the Company's common stock exceeds $30.00 for ten consecutive trading days; and iv) 100% of the options will vest when either (a) the filing of the first marketing application for any pharmaceutical based upon the Company's Multikine technology in any of the USA, Canada, UK, Germany, France, Italy, Spain, Japan, or Australia or (b) the closing price of the Company's common stock exceeds $40.00 for ten consecutive trading days. Read SEC document |
| April 20, 2020 Filed Apr 20, 2020 20:55 UTC |
ZIMMERMAN DANIEL HSenior Vice President
|
GrantOptions · Derivative | 160,000 | $0.01 Strike: $10.93 | $1,600.00 |
DisclosureSEC source: 0001236031-20-000020 · primary_doc.xml · derivative · entry 1 ZIMMERMAN DANIEL H · CIK 0001236028 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 544,453 Underlying: Common Stock · 160,000 shares Expires 2030-04-19 F1 · derivative.exercise_date: These stock options are performance based. Each option entitles the holder to purchase one share of the Company's common stock at a price of $10.93 per share. The stock options vest upon the achievement of the following performance goals: i) 25% of the options will vest when the closing price of the Company's common stock exceeds $20.00 for ten consecutive trading days; ii) 50% of the options will vest when the closing price of the Company's common stock exceeds $25.00 for ten consecutive trading days; iii) 75% of the options will vest when the closing price of the Company's common stock exceeds $30.00 for ten consecutive trading days; and iv) 100% of the options will vest when either (a) the filing of the first marketing application for any pharmaceutical based upon the Company's Multikine technology in any of the USA, Canada, UK, Germany, France, Italy, Spain, Japan, or Australia or (b) the closing price of the Company's common stock exceeds $40.00 for ten consecutive trading days. Read SEC document |
| April 20, 2020 Filed Apr 20, 2020 20:52 UTC |
CIPRIANO JOHNSenior Vice President
|
GrantOptions · Derivative | 160,000 | $0.01 Strike: $10.93 | $1,600.00 |
DisclosureSEC source: 0001236031-20-000019 · primary_doc.xml · derivative · entry 1 CIPRIANO JOHN · CIK 0001282304 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 610,027 Underlying: Common Stock · 160,000 shares Expires 2030-04-19 F1 · derivative.exercise_date: These stock options are performance based. Each option entitles the holder to purchase one share of the Company's common stock at a price of $10.93 per share. The stock options vest upon the achievement of the following performance goals: i) 25% of the options will vest when the closing price of the Company's common stock exceeds $20.00 for ten consecutive trading days; ii) 50% of the options will vest when the closing price of the Company's common stock exceeds $25.00 for ten consecutive trading days; iii) 75% of the options will vest when the closing price of the Company's common stock exceeds $30.00 for ten consecutive trading days; and iv) 100% of the options will vest when either (a) the filing of the first marketing application for any pharmaceutical based upon the Company's Multikine technology in any of the USA, Canada, UK, Germany, France, Italy, Spain, Japan, or Australia or (b) the closing price of the Company's common stock exceeds $40.00 for ten consecutive trading days. Read SEC document |
| April 20, 2020 Filed Apr 20, 2020 20:49 UTC |
TALOR EYALChief Scientific Officer
|
GrantOptions · Derivative | 288,000 | $0.01 Strike: $10.93 | $2,880.00 |
DisclosureSEC source: 0001236031-20-000018 · primary_doc.xml · derivative · entry 1 TALOR EYAL · CIK 0001238028 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,096,646 Underlying: Common Stock · 288,000 shares Expires 2030-04-19 F1 · derivative.exercise_date: These stock options are performance based. Each option entitles the holder to purchase one share of the Company's common stock at a price of $10.93 per share. The stock options vest upon the achievement of the following performance goals: i) 25% of the options will vest when the closing price of the Company's common stock exceeds $20.00 for ten consecutive trading days; ii) 50% of the options will vest when the closing price of the Company's common stock exceeds $25.00 for ten consecutive trading days; iii) 75% of the options will vest when the closing price of the Company's common stock exceeds $30.00 for ten consecutive trading days; and iv) 100% of the options will vest when either (a) the filing of the first marketing application for any pharmaceutical based upon the Company's Multikine technology in any of the USA, Canada, UK, Germany, France, Italy, Spain, Japan, or Australia or (b) the closing price of the Company's common stock exceeds $40.00 for ten consecutive trading days. Read SEC document |
| April 20, 2020 Filed Apr 20, 2020 20:45 UTC |
PRICHEP PATRICIA BSenior Vice President
|
GrantOptions · Derivative | 288,000 | $0.01 Strike: $10.93 | $2,880.00 |
DisclosureSEC source: 0001236031-20-000017 · primary_doc.xml · derivative · entry 1 PRICHEP PATRICIA B · CIK 0001236215 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,066,797 Underlying: Common Stock · 288,000 shares Expires 2030-04-19 F1 · derivative.exercise_date: These stock options are performance based. Each option entitles the holder to purchase one share of the Company's common stock at a price of $10.93 per share. The stock options vest upon the achievement of the following performance goals: i) 25% of the options will vest when the closing price of the Company's common stock exceeds $20.00 for ten consecutive trading days; ii) 50% of the options will vest when the closing price of the Company's common stock exceeds $25.00 for ten consecutive trading days; iii) 75% of the options will vest when the closing price of the Company's common stock exceeds $30.00 for ten consecutive trading days; and iv) 100% of the options will vest when either (a) the filing of the first marketing application for any pharmaceutical based upon the Company's Multikine technology in any of the USA, Canada, UK, Germany, France, Italy, Spain, Japan, or Australia or (b) the closing price of the Company's common stock exceeds $40.00 for ten consecutive trading days. Read SEC document |
| April 20, 2020 Filed Apr 20, 2020 20:41 UTC |
KERSTEN GEERT RDirector · Chief Executive Officer
|
GrantOptions · Derivative | 592,000 | $0.01 Strike: $10.93 | $5,920.00 |
DisclosureSEC source: 0001236031-20-000016 · primary_doc.xml · derivative · entry 1 KERSTEN GEERT R · CIK 0001236030 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,142,309 Underlying: Common Stock · 592,000 shares Expires 2030-04-19 F1 · derivative.exercise_date: These stock options are performance based. Each option entitles the holder to purchase one share of the Company's common stock at a price of $10.93 per share. The stock options vest upon the achievement of the following performance goals: i) 25% of the options will vest when the closing price of the Company's common stock exceeds $20.00 for ten consecutive trading days; ii) 50% of the options will vest when the closing price of the Company's common stock exceeds $25.00 for ten consecutive trading days; iii) 75% of the options will vest when the closing price of the Company's common stock exceeds $30.00 for ten consecutive trading days; and iv) 100% of the options will vest when either (a) the filing of the first marketing application for any pharmaceutical based upon the Company's Multikine technology in any of the USA, Canada, UK, Germany, France, Italy, Spain, Japan, or Australia or (b) the closing price of the Company's common stock exceeds $40.00 for ten consecutive trading days. Read SEC document |
| March 31, 2020 Filed Apr 1, 2020 13:11 UTC |
ZIMMERMAN DANIEL HSenior Vice President
|
GrantCommon Stock | 296 | $11.54 | $3,415.84 |
DisclosureSEC source: 0001236031-20-000015 · primary_doc.xml · nonDerivative · entry 1 ZIMMERMAN DANIEL H · CIK 0001236028 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 114,683 Read SEC document |
| March 31, 2020 Filed Apr 1, 2020 13:09 UTC |
TALOR EYALChief Scientific Officer
|
GrantCommon Stock | 207 | $11.54 | $2,388.78 |
DisclosureSEC source: 0001236031-20-000014 · primary_doc.xml · nonDerivative · entry 1 TALOR EYAL · CIK 0001238028 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 118,695 Read SEC document |
| March 31, 2020 Filed Apr 1, 2020 13:07 UTC |
PRICHEP PATRICIA BSenior Vice President
|
GrantCommon Stock | 317 | $11.54 | $3,658.18 |
DisclosureSEC source: 0001236031-20-000013 · primary_doc.xml · nonDerivative · entry 1 PRICHEP PATRICIA B · CIK 0001236215 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 205,592 Read SEC document |
| March 31, 2020 Filed Apr 1, 2020 13:04 UTC |
KERSTEN GEERT RDirector · Chief Executive Officer
|
GrantCommon Stock | 370 | $11.54 | $4,269.80 |
DisclosureSEC source: 0001236031-20-000012 · primary_doc.xml · nonDerivative · entry 1 KERSTEN GEERT R · CIK 0001236030 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,119,525 Read SEC document |
| February 26, 2020 Filed Feb 27, 2020 12:57 UTC |
Watson Robert EugeneDirector
|
PurchaseCommon Stock | 923 | $10.83 | $9,996.09 |
DisclosureSEC source: 0001236031-20-000011 · primary_doc.xml · nonDerivative · entry 1 Watson Robert Eugene · CIK 0001511858 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,381 F1 · shares: On February 26, 2020, Mr. Watson purchased $10,000 worth of restricted stock directly from the Company at the closing price on February 26, 2020, the most recent closing price available. Read SEC document |
| February 26, 2020 Filed Feb 27, 2020 12:53 UTC |
BAILLAVOINE BRUNO JEAN-MARIEDirector
|
PurchaseCommon Stock | 923 | $10.83 | $9,996.09 |
DisclosureSEC source: 0001236031-20-000010 · primary_doc.xml · nonDerivative · entry 1 BAILLAVOINE BRUNO JEAN-MARIE · CIK 0001646989 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,923 F1 · shares: On February 26, 2020, Mr. Baillavoine purchased $10,000 worth of restricted stock directly from the Company at the closing price on February 26, 2020, the most recent closing price available. Read SEC document |
| February 26, 2020 Filed Feb 27, 2020 12:49 UTC |
YOUNG PETER RDirector
|
PurchaseCommon Stock | 923 | $10.83 | $9,996.09 |
DisclosureSEC source: 0001236031-20-000009 · primary_doc.xml · nonDerivative · entry 1 YOUNG PETER R · CIK 0001238029 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,014 F1 · shares: On February 26, 2020, Dr. Young purchased $10,000 worth of restricted stock directly from the Company at the closing price on February 26, 2020, the most recent closing price available. Read SEC document |
| February 26, 2020 Filed Feb 27, 2020 12:45 UTC |
ZIMMERMAN DANIEL HSenior Vice President
|
PurchaseCommon Stock | 923 | $10.83 | $9,996.09 |
DisclosureSEC source: 0001236031-20-000008 · primary_doc.xml · nonDerivative · entry 1 ZIMMERMAN DANIEL H · CIK 0001236028 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 114,387 F1 · shares: On February 26, 2020, Dr. Zimmerman purchased $10,000 worth of restricted stock directly from the Company at the closing price on February 26, 2020, the most recent closing price available. Read SEC document |
| February 26, 2020 Filed Feb 27, 2020 12:33 UTC |
KERSTEN GEERT RDirector · Chief Executive Officer
|
PurchaseCommon Stock | 4,617 | $10.83 | $50,002.11 |
DisclosureSEC source: 0001236031-20-000006 · primary_doc.xml · nonDerivative · entry 1 KERSTEN GEERT R · CIK 0001236030 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,119,155 F1 · shares: On February 26, 2020, Mr. Kersten purchased $50,000 worth of restricted stock directly from the Company at the closing price on February 26, 2020, the most recent closing price available. Read SEC document |
| February 26, 2020 Filed Feb 27, 2020 12:37 UTC |
PRICHEP PATRICIA BSenior Vice President
|
PurchaseCommon Stock | 1,847 | $10.83 | $20,003.01 |
DisclosureSEC source: 0001236031-20-000007 · primary_doc.xml · nonDerivative · entry 1 PRICHEP PATRICIA B · CIK 0001236215 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 205,275 F1 · shares: On February 26, 2020, Ms. Prichep purchased $20,000 worth of restricted stock directly from the Company at the closing price on February 26, 2020, the most recent closing price available. Read SEC document |
| January 10, 2020 Filed Jan 13, 2020 13:10 UTC |
KERSTEN GEERT RDirector · Chief Executive Officer
|
PurchaseCommon Stock | 6,631 | $7.54 | $49,997.74 |
DisclosureSEC source: 0001236031-20-000005 · primary_doc.xml · nonDerivative · entry 1 KERSTEN GEERT R · CIK 0001236030 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,114,538 F1 · shares: On January 10, 2020, Mr. Kersten purchased $50,000 worth of restricted stock directly from the Company at the closing price on January 9, 2020, the most recent closing price available. Read SEC document |
| December 31, 2019 Filed Jan 3, 2020 15:36 UTC |
ZIMMERMAN DANIEL HSenior Vice President
|
GrantCommon Stock | 373 | $9.15 | $3,412.95 |
DisclosureSEC source: 0001236031-20-000004 · primary_doc.xml · nonDerivative · entry 1 ZIMMERMAN DANIEL H · CIK 0001236028 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 113,464 Read SEC document |
| December 31, 2019 Filed Jan 3, 2020 15:31 UTC |
PRICHEP PATRICIA BSenior Vice President
|
GrantCommon Stock | 401 | $9.15 | $3,669.15 |
DisclosureSEC source: 0001236031-20-000002 · primary_doc.xml · nonDerivative · entry 1 PRICHEP PATRICIA B · CIK 0001236215 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 203,428 Read SEC document |
| December 31, 2019 Filed Jan 3, 2020 15:33 UTC |
TALOR EYALChief Scientific Officer
|
GrantCommon Stock | 262 | $9.15 | $2,397.30 |
DisclosureSEC source: 0001236031-20-000003 · primary_doc.xml · nonDerivative · entry 1 TALOR EYAL · CIK 0001238028 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 118,488 Read SEC document |
| December 31, 2019 Filed Jan 3, 2020 15:28 UTC |
KERSTEN GEERT RDirector · Chief Executive Officer
|
GrantCommon Stock | 483 | $9.15 | $4,419.45 |
DisclosureSEC source: 0001236031-20-000001 · primary_doc.xml · nonDerivative · entry 1 KERSTEN GEERT R · CIK 0001236030 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,107,907 Read SEC document |
| October 25, 2019 Filed Oct 28, 2019 10:32 UTC |
KERSTEN GEERT RDirector · Chief Executive Officer
|
PurchaseCommon Stock | 3,725 | $6.71 | $24,994.75 |
DisclosureSEC source: 0001236031-19-000031 · primary_doc.xml · nonDerivative · entry 1 KERSTEN GEERT R · CIK 0001236030 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,107,424 F1 · shares: On October 25, 2019, Mr. Kersten purchased $25,000 worth of restricted stock directly from the Company at the closing price on October 24, 2019, the most recent closing price available. Read SEC document |
| September 30, 2019 Filed Oct 1, 2019 20:44 UTC |
ZIMMERMAN DANIEL HSenior Vice President
|
GrantCommon Stock | 382 | $8.94 | $3,415.08 |
DisclosureSEC source: 0001236031-19-000030 · primary_doc.xml · nonDerivative · entry 1 ZIMMERMAN DANIEL H · CIK 0001236028 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 113,091 Read SEC document |
| September 30, 2019 Filed Oct 1, 2019 20:41 UTC |
TALOR EYALChief Scientific Officer
|
GrantCommon Stock | 268 | $8.94 | $2,395.92 |
DisclosureSEC source: 0001236031-19-000029 · primary_doc.xml · nonDerivative · entry 1 TALOR EYAL · CIK 0001238028 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 118,226 Read SEC document |
| September 30, 2019 Filed Oct 1, 2019 20:37 UTC |
PRICHEP PATRICIA BSenior Vice President
|
GrantCommon Stock | 410 | $8.94 | $3,665.40 |
DisclosureSEC source: 0001236031-19-000028 · primary_doc.xml · nonDerivative · entry 1 PRICHEP PATRICIA B · CIK 0001236215 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 203,027 Read SEC document |
| September 30, 2019 Filed Oct 1, 2019 20:34 UTC |
KERSTEN GEERT RDirector · Chief Executive Officer
|
GrantCommon Stock | 461 | $8.94 | $4,121.34 |
DisclosureSEC source: 0001236031-19-000027 · primary_doc.xml · nonDerivative · entry 1 KERSTEN GEERT R · CIK 0001236030 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,103,699 Read SEC document |
| September 17, 2019 Filed Sep 18, 2019 21:02 UTC |
CIPRIANO JOHNSenior Vice President
|
SaleCommon Stock | 8,000 | $8.69 | $69,559.20 |
DisclosureSEC source: 0001236031-19-000026 · primary_doc.xml · nonDerivative · entry 1 CIPRIANO JOHN · CIK 0001282304 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,108 Read SEC document |
| September 04, 2019 Filed Sep 5, 2019 11:54 UTC |
KERSTEN GEERT RDirector · Chief Executive Officer
|
GrantCommon Stock | 3,492 | $7.16 | $25,002.72 |
DisclosureSEC source: 0001236031-19-000023 · primary_doc.xml · nonDerivative · entry 1 KERSTEN GEERT R · CIK 0001236030 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,102,746 Read SEC document |
| September 04, 2019 Filed Sep 5, 2019 12:00 UTC |
ZIMMERMAN DANIEL HSenior Vice President
|
GrantCommon Stock | 2,375 | $7.16 | $17,005.00 |
DisclosureSEC source: 0001236031-19-000025 · primary_doc.xml · nonDerivative · entry 1 ZIMMERMAN DANIEL H · CIK 0001236028 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 112,302 Read SEC document |
| September 04, 2019 Filed Sep 5, 2019 11:57 UTC |
PRICHEP PATRICIA BSenior Vice President
|
GrantCommon Stock | 2,095 | $7.16 | $15,000.20 |
DisclosureSEC source: 0001236031-19-000024 · primary_doc.xml · nonDerivative · entry 1 PRICHEP PATRICIA B · CIK 0001236215 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 202,180 Read SEC document |
| August 28, 2019 Filed Aug 29, 2019 21:14 UTC |
CIPRIANO JOHNSenior Vice President
|
SaleCommon Stock | 8,000 | $7.03 | $56,208.00 |
DisclosureSEC source: 0001236031-19-000022 · primary_doc.xml · nonDerivative · entry 1 CIPRIANO JOHN · CIK 0001282304 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 91,108 Read SEC document |
| June 03, 2019 Filed Jun 4, 2019 01:03 UTC |
KERSTEN GEERT RDirector · Chief Executive Officer
|
GrantCommon Stock | 6,631 | $3.77 | $24,998.87 |
DisclosureSEC source: 0001236031-19-000021 · primary_doc.xml · nonDerivative · entry 1 KERSTEN GEERT R · CIK 0001236030 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,099,254 Read SEC document |
| May 21, 2019 Filed May 22, 2019 01:18 UTC |
YOUNG PETER RDirector
|
PurchaseCommon Stock | 2,000 | $5.00 | $10,000.00 |
DisclosureSEC source: 0001236031-19-000020 · primary_doc.xml · nonDerivative · entry 1 YOUNG PETER R · CIK 0001238029 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,091 Read SEC document |
| May 07, 2019 Filed May 8, 2019 12:12 UTC |
Watson Robert EugeneDirector
|
GrantCommon Stock | 1,458 | $6.86 | $10,001.88 |
DisclosureSEC source: 0001236031-19-000019 · primary_doc.xml · nonDerivative · entry 1 Watson Robert Eugene · CIK 0001511858 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,458 Read SEC document |
| May 07, 2019 Filed May 8, 2019 12:09 UTC |
ZIMMERMAN DANIEL HSenior Vice President
|
GrantCommon Stock | 4,373 | $6.86 | $29,998.78 |
DisclosureSEC source: 0001236031-19-000018 · primary_doc.xml · nonDerivative · entry 1 ZIMMERMAN DANIEL H · CIK 0001236028 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 109,927 Read SEC document |
| May 07, 2019 Filed May 8, 2019 12:06 UTC |
CIPRIANO JOHNSenior Vice President
|
GrantCommon Stock | 2,915 | $6.86 | $19,996.90 |
DisclosureSEC source: 0001236031-19-000017 · primary_doc.xml · nonDerivative · entry 1 CIPRIANO JOHN · CIK 0001282304 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 99,108 Read SEC document |
| May 07, 2019 Filed May 8, 2019 12:03 UTC |
PRICHEP PATRICIA BSenior Vice President
|
GrantCommon Stock | 7,289 | $6.86 | $50,002.54 |
DisclosureSEC source: 0001236031-19-000016 · primary_doc.xml · nonDerivative · entry 1 PRICHEP PATRICIA B · CIK 0001236215 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,085 Read SEC document |
| May 07, 2019 Filed May 8, 2019 12:00 UTC |
KERSTEN GEERT RDirector · Chief Executive Officer
|
GrantCommon Stock | 14,577 | $6.86 | $99,998.22 |
DisclosureSEC source: 0001236031-19-000015 · primary_doc.xml · nonDerivative · entry 1 KERSTEN GEERT R · CIK 0001236030 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,092,623 Read SEC document |
| April 11, 2019 Filed Apr 12, 2019 20:51 UTC |
CIPRIANO JOHNSenior Vice President
|
GrantOptions · Derivative | 206,880 | $0.01 Strike: $5.65 | $2,068.80 |
DisclosureSEC source: 0001236031-19-000011 · primary_doc.xml · derivative · entry 1 CIPRIANO JOHN · CIK 0001282304 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 450,427 Underlying: Common Stock · 206,880 shares Expires 2029-04-10 F1 · shares: Part of the options were awarded in recognition of the salary that has been deferred over an approximate 12 month period and not paid in cash. These options awarded are equal to 0.25 option for every dollar deferred. F2 · derivative.exercise_date: The stock options vest in three (3) equal annual installments commencing one year after the grant date. Read SEC document |
| April 11, 2019 Filed Apr 12, 2019 21:03 UTC |
Watson Robert EugeneDirector
|
GrantOptions · Derivative | 160,000 | $0.01 Strike: $5.65 | $1,600.00 |
DisclosureSEC source: 0001236031-19-000014 · primary_doc.xml · derivative · entry 1 Watson Robert Eugene · CIK 0001511858 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250,000 Underlying: Common Stock · 160,000 shares Expires 2029-04-10 F1 · derivative.exercise_date: The stock options vest in three (3) equal annual installments commencing one year after the grant date. Read SEC document |
| April 11, 2019 Filed Apr 12, 2019 21:00 UTC |
BAILLAVOINE BRUNO JEAN-MARIEDirector
|
GrantOptions · Derivative | 160,000 | $0.01 Strike: $5.65 | $1,600.00 |
DisclosureSEC source: 0001236031-19-000013 · primary_doc.xml · derivative · entry 1 BAILLAVOINE BRUNO JEAN-MARIE · CIK 0001646989 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 277,500 Underlying: Common Stock · 160,000 shares Expires 2029-04-10 F1 · derivative.exercise_date: The stock options vest in three (3) equal annual installments commencing one year after the grant date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.